Eli Lilly and Company (LLY) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5324571083

Eli Lilly and Company, traded on the New York Stock Exchange under the ticker symbol LLY, is a global leader in discovering, developing, and distributing pharmaceuticals for various medical conditions.

The company's diverse product portfolio includes treatments for diabetes, with offerings such as Basaglar, Humalog, and insulin lispro, among others, catering to different needs of individuals managing the condition.

In addition to diabetes medications, Eli Lilly and Company also provides treatments for cancer, including Alimta for non-small cell lung cancer and Cyramza for metastatic gastric cancer, demonstrating their commitment to fighting serious illnesses.

Furthermore, the company offers innovative solutions for conditions like rheumatoid arthritis, plaque psoriasis, and depressive disorders through medications such as Olumiant, Taltz, and Cymbalta, respectively, emphasizing their dedication to improving quality of life.

Notably, Eli Lilly and Company has made significant contributions during the COVID-19 pandemic with drugs like Bamlanivimab and etesevimab, showcasing their agility and focus on addressing urgent global health challenges.

With a rich history dating back to 1876, Eli Lilly and Company's headquarters are in Indianapolis, Indiana, reflecting its deep roots in the medical and pharmaceutical industries. To learn more, you can visit their website at https://www.lilly.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Eli Lilly and Company (LLY) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Eli Lilly and Company (LLY) - Stock & Dividends

LLY Stock Overview

Market Cap in USD 730,264m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1978-01-13

LLY Stock Ratings

Growth 5y 9.56
Fundamental 2.71
Dividend 8.25
Rel. Performance vs Sector 6.59
Analysts 4.18/5
Fair Price Momentum 1024.06 USD
Fair Price DCF -

LLY Dividends

Yield 12m 0.63%
Yield on Cost 5y 4.39%
Dividends CAGR 5y 11.87%
Payout Consistency 99.7%

LLY Growth Ratios

Growth 12m 100.69%
Growth Correlation 12m 83%
Growth Correlation 3m 43%
CAGR 5y 47.34%
Sharpe Ratio 12m 3.22
Alpha vs SP500 12m 84.58
Beta vs SP500 5y weekly 0.61
ValueRay RSI 7.15
Volatility GJR Garch 1y 28.14%
Price / SMA 50 -2.12%
Price / SMA 200 21.72%
Current Volume 1717k
Average Volume 20d 2353.6k

External Links for LLY Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of LLY stocks?
As of April 19, 2024, the stock is trading at USD 745.95 with a total of 1,717,042 shares traded.
Over the past week, the price has changed by -1.80%, over one month by -2.19%, over three months by +19.88% and over the past year by +103.35%.
What is the forecast for LLY stock price target?
According to ValueRays Forecast Model, LLY Eli Lilly and Company will be worth about 1129.3 in April 2025. The stock is currently trading at 745.95. This means that the stock has a potential upside of +51.4%.
Issuer Forecast Upside
Wallstreet Target Price 818.9 9.78%
Analysts Target Price 603.6 -19.1%
ValueRay Target Price 1129.3 51.4%

Eli Lilly and Company: A Journey Through Innovation and Market Presence

Introduction to Eli Lilly and Company

Eli Lilly and Company, founded in 1876 by Colonel Eli Lilly, has established itself as a beacon of innovation in the pharmaceutical industry. Eli Lilly's commitment to creating high-quality medicines has significantly impacted healthcare on a global scale.

The Early Days and Evolution

In its early years, Eli Lilly and Company focused on the production of medicinal drugs to meet high-quality standards, which set it apart from its competitors. The founder's vision for a company deeply grounded in scientific research and development laid the foundation for a future of groundbreaking achievements in medicine.

Core Businesses and Key Achievements

At its core, Eli Lilly and Company develops, manufactures, and markets pharmaceuticals for a wide range of conditions. Its innovative portfolio includes treatments for diabetes, cancer, autoimmune diseases, and mental health disorders, among others. Eli Lilly has contributed significantly to medical advancements, with insulin and Prozac being notable examples of its impactful products.

Expansion and Side Ventures

Over the years, Eli Lilly has expanded its reach beyond its core pharmaceutical business. It has ventured into animal health, biotechnology, and healthcare technology solutions, demonstrating its versatility and commitment to addressing global health challenges from multiple fronts.

Current Market Status

Today, Eli Lilly and Company continues to stand as a leader in the pharmaceutical industry, with a strong presence in global markets. As of the latest reports, it sustains robust financial performance and a dynamic research pipeline poised to deliver new medical solutions. The company's commitment to innovation, coupled with its strategic business expansions, positions it well for ongoing and future success.